13,139 resources
Start Prev Rows 12000 - 12200 Next
| Package | Version | Identity | Name/Title | Status | FMM | WG | Date | Auth | Source(s) |
|---|---|---|---|---|---|---|---|---|---|
| signal.core.r4 | R4 | questionnaire-ccars-type-of-discharge | Questionnaire CCARS Type Of Discharge | draft | 1 | pa | hl7 | ||
| ca.on.dhdr.r4.v4 | R4 | dispense-category | Dispense Category | active | hl7 | ||||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.974 | Message Error Condition Codes (HL7) | active | 2018-01 | tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7806 | Assisted Living Exposure Type (RIBD) | active | 2018-01 | sct tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7718 | Healthcare Exposure Type (RIBD) | active | 2018-01 | sct tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3401 | Facility / Visit Type (Syndromic Surveillance) | active | 2019-01 | cdc nucc | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.8015 | Food Product Consumed (Brucellosis) | active | 2022-01 | sct tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3260 | Count Group Type (Flu) | active | 2009-01 | oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7940 | Healthcare Occupation (COVID-19) | active | 2020-01 | sct tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7717 | Legionella Exposure Setting (RIBD) | active | 2018-01 | sct tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.984 | Dwelling Type | active | 2008-01 | sct oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3081 | Fetal Neonatal Infection Type (FDD) | active | 2008-01 | sct tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3091 | Maternal Infection (FDD) | active | 2008-01 | sct tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3136 | PCR Performed Lab Location (VPD) | active | 2008-01 | oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3139 | Serology Performed Lab Location (Pertussis) | active | 2008-01 | oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7330 | Performing Laboratory Type (VPD) | active | 2020-01 | tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3159 | Reporting Lab Type | active | 2008-01 | tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7493 | Performing Lab Type (Arbovirus) | active | 2016-01 | oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3090 | Lettuce Type (FDD) | active | 2018-01 | sct tho oid | |||
| hl7.fhir.us.davinci-vbpr | R4 | lob | Line of Business Value Set | trial-use | 1 | cqi | 2025-07 | hl7 | |
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7949 | Treatment Type (COVID-19) | active | 2020-01 | sct tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7997 | Treatment Type (Anthrax) | active | 2020-01 | sct tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3160 | Microscopic Exam Type (TB) | active | 2008-01 | sct | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7196 | Non Treponemal Serologic Test (STD) | active | 2020-01 | oid loinc | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3093 | Non Pork Type (FDD) | active | 2008-01 | tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3095 | Outbreak Type (FDD) | active | 2008-01 | sct tho oid | |||
| hl7.fhir.us.davinci-vbpr | R4 | vbp-payment-stream | Payment Stream Value Set | trial-use | 1 | cqi | 2025-07 | hl7 | fhir |
| hl7.fhir.us.davinci-drug-formulary | R4 | PlanContactTypeVS | Type of plan contact | trial-use | phx | 2025-02 | hl7 | fhir tho | |
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3096 | Pork Type (FDD) | active | 2008-01 | sct tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3100 | Seafood Type (FDD) | active | 2018-01 | oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7692 | Rehab Type (RIBD) | active | 2018-01 | sct | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7939 | Residence Type (COVID-19) | active | 2020-01 | sct tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.825 | Referral Disposition (HL7) | active | 2008-01 | tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7748 | Epidemiological Risk Factors (TB) | active | 2019-01 | sct tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7708 | Rupture Type (RIBD) | active | 2018-01 | sct | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7998 | Severe Weather Type (Leptospirosis) | active | 2020-01 | sct | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7683 | Substance Abuse (RIBD) | active | 2019-01 | sct tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7329 | Type of Testing at CDC (NND) | active | 2020-01 | sct tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3143 | Tetanus Type (VPD) | active | 2008-01 | sct tho | |||
| hl7.fhir.us.mdi | R4 | vs-tracking-number-type | Tracking Number Type | trial-use | 3 | pher | 2025-07 | hl7 | fhir |
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7197 | Treponemal Serologic Test (STD) | active | 2020-01 | oid loinc | |||
| signal.core.r4 | R4 | questionnaire-ccars-type-of-update | Questionnaire CCARS Type Of Update | draft | 1 | pa | hl7 | ||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7335 | Vaccine Administered (Pertussis) | active | 2020-01 | cvx tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7448 | Vaccine Type (NND) | active | 2022-01 | cvx tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7688 | Vaccine Type (RIBD) | active | 2018-01 | cvx tho oid | |||
| hl7.fhir.us.davinci-ra | R4 | cc-type | Condition Category Type | trial-use | 2 | cqi | 2025-07 | hl7 | fhir |
| hl7.fhir.us.davinci-vbpr | R4 | vbp-performance-metric | Performance Metric | trial-use | 1 | cqi | 2025-07 | hl7 | fhir |
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3254 | Employment Status (Flu) | active | 2009-01 | sct tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3314 | Specimen Type (Malaria) | active | 2017-01 | sct tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7977 | Brucella Exposure (Brucellosis) | active | 2021-01 | sct tho | |||
| hl7.fhir.us.pacio-adi | R4 | ADIDocumentationTypeVS | Documentation Types | trial-use | 2 | pe | 2025-08 | hl7 | sct loinc |
| signal.core.r4 | R4 | signal-organization-type | Signal Organization Type | draft | 2023-07 | hl7 | tho | ||
| hl7.fhir.us.Davinci-drug-formulary | R4 | usdf-PharmacyTypeVS | Pharmacy Type VS | draft | 2020-01 | hl7 | fhir | ||
| hl7.fhir.us.vdor | R4 | vdor-types-of-treatment-for-substance-use-disorder-vs | VDOR Types of Treatment for Substance Use Disorder | informative | pher | 2025-06 | hl7 | fhir | |
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3121 | Birth Attendees (VPD) | active | 2008-01 | sct tho oid | |||
| hl7.fhir.us.mcode | R4 | mcode-benign-uncertain-neoplasm-brain-cns-disorder-vs | Benign Neoplasm of Brain and CNS Disorder Value Set | active | 4 | cic | 2025-02 | hl7 | sct icd |
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3058 | Cancer Type | active | 2008-01 | sct | |||
| hl7.fhir.us.mcode | R4 | mcode-carcinoma-in-situ-disorder-vs | Carcinoma In-Situ Disorder Value Set | active | 4 | cic | 2025-02 | hl7 | sct icd |
| hl7.fhir.us.davinci-pas | R4 | PASCommunicationRequestMedium | PAS Communication Medium Value Set | trial-use | 3 | fm | 2025-07 | hl7 | fhir x12 |
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3210 | Contact Type (Hepatitis B) | active | 2009-01 | sct oid | |||
| us.nlm.vsac | R4 | 2.16.840.1.113883.11.20.9.69.5 | Advance Directives Content Types | active | 2024-04 | hl7 | loinc | ||
| hl7.fhir.us.mcode | R4 | mcode-cytologic-evidence-malignancy-vs | Cytologic Evidence of Malignancy Value Set | active | 4 | cic | 2025-02 | hl7 | sct icd |
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3211 | Material exposure type | active | 2009-01 | sct oid | |||
| hl7.fhir.us.mcode | R4 | mcode-hypereosinophilic-syndrome-disorder-vs | Specific Diagnosis of Cancer Value Set | active | 4 | cic | 2025-02 | hl7 | sct icd |
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7732 | Infection Type (RIBD) | active | 2018-01 | sct tho oid | |||
| hl7.fhir.us.davinci-drug-formulary | R4 | InsuranceItemTypeVS | Insurance item type | trial-use | phx | 2025-02 | hl7 | fhir | |
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3133 | Live Birth Outcome (Rubella) | active | 2008-01 | oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.1006 | Type of Long Term Care Facility | active | 2019-01 | tho oid | |||
| hl7.fhir.us.mcode | R4 | mcode-melanoma-in-situ-disorder-vs | Melanoma In-Situ Disorder Value Set | active | 4 | cic | 2025-02 | hl7 | sct icd |
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3135 | Non-Live Birth Outcome (VPD) | active | 2008-01 | sct | |||
| hl7.fhir.us.mcode | R4 | mcode-primary-malignant-neoplasm-disorder-vs | Primary Malignant Neoplasm Disorder Value Set | active | 4 | cic | 2025-02 | hl7 | sct icd |
| hl7.fhir.us.mcode | R4 | mcode-primary-cancer-disorder-vs | Primary Cancer Disorder Value Set | active | 4 | cic | 2025-02 | hl7 | fhir |
| hl7.fhir.us.mcode | R4 | mcode-cancer-staging-prognostic-factor-type-vs | Cancer Staging Prognostic Factors Types | active | cic | 2025-02 | hl7 | sct | |
| hl7.fhir.us.mcode | R4 | mcode-secondary-cancer-disorder-vs | Secondary Cancer Disorder Value Set | active | 4 | cic | 2025-02 | hl7 | sct icd |
| hl7.fhir.us.davinci-pas | R4 | PASSupportingInfoType | PAS Supporting Info Type Value Set | trial-use | 3 | fm | 2025-07 | hl7 | fhir |
| us.nlm.vsac | R4 | 2.16.840.1.113883.10.20.22.5.300 | Transmission Based Precaution Types | active | 2024-06 | hl7 | sct | ||
| hl7.cda.us.eyecare | R5 | AidToVisionCodes | Aid to Vision Codes | draft | 2024-02 | hl7 | sct | ||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7941 | Job Setting (COVID-19) | active | 2020-01 | sct tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7647 | Typhoid Paratyphoid Serotype (FDD) | active | 2017-01 | sct | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3111 | Typhoid Signs Symptoms (FDD) | active | 2008-01 | sct tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3590 | Pulse Oximetry Unit | active | 2010-01 | ucum | |||
| fhir.virtually.healthcare | R4 | UKCorrelationIdentifier | UK Common Resource Identifiers | draft | 2025-08 | hl7 | internal | ||
| fhir.virtually.healthcare | R4 | UKNationalIdentifiers | UK National Insurance Identifiers | draft | 2025-08 | hl7 | internal | ||
| fhir.virtually.healthcare | R4 | ProfessionalLicense | UK Professional License | draft | 2025-08 | hl7 | internal | ||
| fhir.virtually.healthcare | R4 | StaffNumber | UK StaffNumber | draft | 2025-08 | hl7 | internal | ||
| hl7.fhir.us.davinci-pct | R4 | USClaimDRGCodes | US Claim DRG Codes | trial-use | fm | 2025-08 | hl7 | cms | |
| fhir.cdc.opioid-cds-r4 | R4 | condition-us-core-health-concern-category | US Core Health Concern Condition Category | active | 2023-05 | hl7 | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.973 | City | active | 2020-01 | oid | |||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1196.4469 | Cabotegravir Injectable Products | active | 2024-05 | hl7 | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1196.4470 | Emtricitabine oral for HIV PrEP | active | 2024-05 | hl7 | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1196.4474 | HIV Laboratory Based Tests | active | 2024-05 | hl7 | loinc | ||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3322 | Underlying Conditions (IPD) | active | 2010-01 | sct tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7681 | Underlying Condition (RIBD) | active | 2018-01 | sct tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7947 | Risk Factor (COVID-19) | active | 2020-01 | sct tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3112 | Underlying Conditions | active | 2008-01 | sct tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3402 | Age Unit (Syndromic Surveillance) | active | 2011-01 | ucum tho | |||
| hl7.fhir.us.codex-radiation-therapy | R4 | codexrt-image-guided-radiotherapy-energy-unit-vs | Image Guided Radiotherapy Energy Unit Value Set | draft | cgp | 2025-02 | hl7 | ucum | |
| hl7.fhir.us.codex-radiation-therapy | R4 | codexrt-radiotherapy-energy-unit-vs | Radiotherapy Energy Unit Value Set | draft | cgp | 2025-02 | hl7 | ucum | |
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7667 | Eosinophil Units | active | 2018-01 | ucum | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.891 | Height Unit | active | 2008-01 | ucum | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7372 | Time Units (NCHS) | active | 2015-01 | ucum tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.879 | Weight Unit | active | 2008-01 | ucum | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7906 | Test result units (ARLN) | active | 2019-01 | ucum | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.838 | Units of Measure | active | 2015-01 | ucum | |||
| hl7.fhir.us.pq-cmc-fda | R5 | pqcmc-non-percentage-units | Non-Percentage Units | trial-use | 2 | brr | 2025-07 | hl7 | fhir |
| hl7.fhir.us.pq-cmc-fda | R5 | pqcmc-percentage-units | Percentage Units | trial-use | 2 | brr | 2025-07 | hl7 | ucum |
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.920 | Blood Pressure Unit | active | 2008-01 | ucum | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.878 | Age unit | active | 2015-01 | ucum tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.919 | Temperature Unit | active | 2008-01 | ucum | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7819 | Unit of Measure (TB) | active | 2018-01 | ucum | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7451 | Type of Testing at CDC (VZ) | active | 2015-12 | sct tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7452 | Age Unit (NND) | active | 2015-12 | ucum tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7453 | Body Region(s) of Rash | active | 2018-01 | sct tho oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7454 | Character of Lesions | active | 2015-12 | sct tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7474 | Type of Complication (VZ) | active | 2017-01 | sct tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7456 | Lab Test Type (Varicella) | active | 2018-01 | oid loinc | |||
| us.nlm.vsac | R4 | 2.16.840.1.113883.11.20.9.41 | Tobacco Use | active | 2024-06 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1032.90 | Gestational Diabetes | active | 2024-06 | hl7 | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.2.1921 | Beta Blocker Therapy Ingredient | active | 2024-02 | hl7 | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1493 | Beta Blocker Therapy Ingredient | active | 2017-05 | hl7 | vsac | ||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.822 | Referral Priority (HL7) | active | 2008-01 | tho | |||
| fhir.cdc.opioid-cds-r4 | R4 | cocaine-urine-drug-screening-tests | Cocaine urine drug screening tests | active | 2023-05 | hl7 | |||
| fhir.cdc.opioid-cds-r4 | R4 | fentanyl-type-urine-drug-screening-tests | Fentanyl-type urine drug screening tests | active | 2023-05 | hl7 | |||
| fhir.cdc.opioid-cds-r4 | R4 | opiate-specific-urine-drug-screening-tests | Opiate specific urine drug screening tests | active | 2023-05 | hl7 | |||
| fhir.cdc.opioid-cds-r4 | R4 | phencyclidine-urine-drug-screening-tests | Phencyclidine urine drug screening tests | active | 2023-05 | hl7 | |||
| fhir.cdc.opioid-cds-r4 | R4 | synthetic-opioid-urine-drug-screening-tests | Synthetic opioid urine drug screening tests | active | 2023-05 | hl7 | |||
| fhir.cdc.opioid-cds-r4 | R4 | all-urine-drug-screening-tests | All urine drug screening tests | active | 2023-11 | hl7 | internal | ||
| fhir.cdc.opioid-cds-r4 | R4 | methadone-urine-drug-screening-tests | Methadone urine drug screening tests | active | 2023-05 | hl7 | loinc | ||
| fhir.cdc.opioid-cds-r4 | R4 | amphetamine-urine-drug-screening-tests | Amphetamine-class drugs and metabolite urine tests | active | 2023-05 | hl7 | loinc | ||
| hl7.fhir.us.vdor | R4 | vdor-use-of-prescription-morphine-vs | VDOR Use of Prescription Morphine | informative | pher | 2025-06 | hl7 | fhir | |
| signal.core.r4 | R4 | contact-point-use | ContactPointUse | draft | 0 | fhir | 2019-10 | hl7 | fhir |
| us.cdc.phinvads | R4 | 2.16.840.1.114222.2.11.7101 | VPD Reason for Study | active | 2013-01 | oid | |||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.1444.3.227 | Neoplasm of Brain | active | 2024-07 | hl7 | icd | ||
| hl7.fhir.us.carin-bb | R4 | C4BBAdjudicationCategoryDiscriminator | C4BB Adjudication Category Discriminator Value Set | trial-use | fm | 2025-02 | hl7 | fhir | |
| hl7.fhir.us.davinci-pdex | R4 | PDexAdjudicationCategoryDiscriminator | PDex Adjudication Category Discriminator | informative | fm | 2025-06 | hl7 | fhir | |
| hl7.fhir.us.carin-bb | R4 | C4BBSupportingInfoType | C4BB SupportingInfo Type Value Set | trial-use | fm | 2025-02 | hl7 | fhir | |
| hl7.fhir.us.davinci-pdex | R4 | PDexSupportingInfoType | PDex SupportingInfo Type | informative | fm | 2025-06 | hl7 | fhir | |
| hl7.fhir.us.carin-bb | R4 | C4BBTotalCategoryDiscriminator | C4BB Total Category Discriminator Value Set | trial-use | fm | 2025-02 | hl7 | fhir | |
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7367 | Exposure Time Frame (NND) | active | 2015-01 | oid | |||
| us.nlm.vsac | R4 | 2.16.840.1.113883.11.20.9.44 | Mental and Functional Status Response | active | 2024-06 | hl7 | sct | ||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.5015 | Role (PHLIP) | active | 2011-01 | tho oid | |||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.1444.5.244 | Anthracycline Injectable | active | 2024-10 | hl7 | vsac | ||
| hl7.fhir.us.core | R4 | us-core-clinical-result-observation-category | US Core Clinical Result Observation Category | trial-use | 3 | cgp | 2023-04 | hl7 | tho |
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7378 | Death Reporting Name Type Code (NCHS) | active | 2016-01 | tho | |||
| us.nlm.vsac | R4 | 2.16.840.1.113883.1.11.11610 | x_ActRelationshipDocument | active | 2024-06 | hl7 | tho | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.1.11.16926 | HL7 BasicConfidentialityKind | active | 2024-06 | hl7 | tho | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1029.67 | Other Health Care Facility | active | 2025-05 | hl7 | sct | ||
| us.cdc.phinvads | R4 | 1.3.6.1.4.1.19376.1.7.3.1.1.15.2.2 | JCIH-EHDI Outpatient Encounter | active | 2010-01 | tho | |||
| hl7.fhir.us.pacio-pfe | R4 | pfe-survey-category-vs | Personal Functioning and Engagement Survey Value Set | trial-use | 3 | pc | 2025-07 | hl7 | tho |
| hl7.fhir.us.icsr-ae-reporting | R4 | ICSRAESeriousness | ICSR Top-Level Seriousness | draft | 2023-08 | hl7 | tho | ||
| signal.core.r4 | R4 | data-absent-reason | DataAbsentReason | normative | 5 | fhir | 2019-10 | hl7 | tho |
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1240.4 | Asked Declined Data Absent Reason | active | 2023-06 | hl7 | tho | ||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7442 | Death Reporting Event Type (NCHS) | active | 2016-01 | tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3363 | Patient Class (IIS) | active | 2010-01 | tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3365 | Relationship (IIS) | active | 2010-01 | tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3366 | Financial Class (IIS) | active | 2010-01 | oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3372 | Identifier Type (IIS) | active | 2010-01 | tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3373 | Organizational Name Type (IIS) | active | 2010-01 | tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3374 | Query Response Status (IIS) | active | 2018-01 | tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3384 | Publicity Code (IIS) | active | 2010-01 | tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3377 | Immunization Registry Status (HL7) | active | 2010-01 | tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3378 | Immunization Registry Status (IIS) | active | 2010-01 | tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3379 | Query Name (IIS) | active | 2010-01 | oid | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.814 | Religion (HL7) | active | 2008-01 | tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.816 | Route of Administration (HL7) | active | 2008-01 | tho | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.812 | Production Class (HL7) | active | 2008-01 | tho | |||
| signal.core.r4 | R4 | questionnaire-dacods-admission-route-of-administration | Questionnaire DACODS Admission Route Of Administration | draft | 1 | pa | hl7 | ||
| signal.core.r4 | R4 | questionnaire-dacods-discharge-route-of-administration | Questionnaire DACODS Discharge Route Of Administration | draft | 1 | pa | hl7 | ||
| fhir.virtually.healthcare | R4 | VHConditionCode | VH Condition Code | draft | 2025-08 | hl7 | sct | ||
| fhir.virtually.healthcare | R4 | VHImmunisationCode | VH Immunisation Code | draft | 2025-08 | hl7 | sct | ||
| fhir.virtually.healthcare | R4 | VHMedicationCode | VH Medication Code | draft | 2025-08 | hl7 | sct | ||
| fhir.virtually.healthcare | R4 | VHObservationCode | VH Observation Code | draft | 2025-08 | hl7 | sct | ||
| fhir.virtually.healthcare | R4 | VHObservationValueCode | VH Observation Value Code | draft | 2025-08 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.9 | ER Test for Orserdu | active | 2023-08 | hl7 | ncit | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.185 | Spinal Surgery | active | 2024-06 | hl7 | cms | ||
| fhir.giis | R4 | VaccinationSiteVS | Vaccination body site | draft | 2025-07 | hl7 | internal | ||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7689 | Vaccination Information Source (RIBD) | active | 2018-01 | sct tho oid | |||
| fhir.giis | R4 | VaccinationReasonVS | Vaccination reason | draft | 2025-07 | hl7 | internal | ||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.934 | Vaccines administered (CVX) | active | 2022-01 | cvx | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.3410 | Vaccine Not Given Reasons (NETSS) | active | 2011-01 | sct tho oid | |||
| fhir.giis | R4 | VaccineVS | Vaccine codes | draft | 2025-07 | hl7 | internal | ||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.7646 | Vaccine Received (FDD) | active | 2017-01 | cvx | |||
| us.cdc.phinvads | R4 | 2.16.840.1.114222.4.11.1049 | Substance Administered (CRA) | active | 2008-01 | cvx | |||
| hl7.fhir.us.registry-protocols | R4 | NCDRErrorsVS | NCDRErrorsVS | active | cic | 2023-11 | hl7 | fhir | |
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.526.3.1489 | ACE Inhibitor or ARB or ARNI Ingredient | active | 2023-02 | hl7 | vsac | ||
| hl7.fhir.us.davinci-pct | R4 | PCTAdjudicationCategoryVS | PCT GFE Item Adjudication Value Set | trial-use | fm | 2025-08 | hl7 | fhir tho | |
| us.nlm.vsac | R4 | 2.16.840.1.113883.10.20.22.5.305 | Microbiology and Antimicrobial Susceptibility Tests | active | 2024-06 | hl7 | loinc | ||
| hl7.fhir.us.directory-query | R4 | OrganizationAffiliationRoleVS | OrganizationAffiliation Roles | active | 2022-12 | hl7 | fhir | ||
| hl7.fhir.us.davinci-pdex-plan-net | R4 | OrganizationAffiliationRoleVS | OrganizationAffiliation Roles | trial-use | fm | 2025-02 | hl7 | fhir | |
| hl7.fhir.us.ndh | R4 | OrganizationAffiliationRoleVS | OrganizationAffiliation Roles | trial-use | pa | 2025-07 | hl7 | fhir tho | |
| hl7.fhir.us.directory-attestation | R4 | OrganizationAffiliationRoleVS | OrganizationAffiliation Roles | active | 2022-12 | hl7 | fhir | ||
| hl7.fhir.us.qicore | R4 | qicore-present-on-admission | QICore Present On Admission Codes | trial-use | 4 | cqi | 2021-05 | hl7 | cms |
| fhir.nigeriaImmunization | R4 | register-client-valueset | IMMZ.C Value Set for Registering Clients | active | 2025-08 | hl7 | internal | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.11.20.9.37 | TargetSite Qualifiers | active | 2024-06 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1099.29 | Allergy Clinical Status | active | 2024-06 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.1.11.1 | Administrative Gender (HL7 V3) | active | 2024-06 | hl7 | tho | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.1.11.20.2 | Advance Directive Type Code | active | 2024-06 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.88.12.3221.8.9 | Body Site Value Set | active | 2024-06 | hl7 | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.1.11.18877 | Coverage Role Type Value Set | active | 2024-06 | hl7 | tho | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.11.20.9.26 | EntityPersonNamePartQualifier | active | 2024-06 | hl7 | tho |
FHIR